PT -期刊文章盟(Sanjeev Kothare AU -萨米Aboumatar AU -大卫Burdette盟-鲁本Kuzniecky AU -格鲁吉亚Montouris AU -威廉·罗森菲尔德盟Steve Chung TI -专家意见:一种新的治疗算法Lennox-Gastaut综合症(LGS)在成人患者(p3.5 - 006) DP - 2019年4月09年TA -神经病学第六PG - p3.5 - 006 - 92 IP - 15补充4099 - //www.ez-admanager.com/content/92/15_supplement/p3.5 006. - 006.短4首页100 - //www.ez-admanager.com/content/92/15_supplement/p3.5 - -全所以Neurology2019 4月09年;92 AB -目的:开发一种新的治疗成人LGS算法。背景:LGS的特征是多种发作类型、脑电图异常模式和智力残疾。随着患者的成熟,因为目前的治疗算法都不是很适合于成人LGS新诊断或护理经历过渡从儿童到成人服务,需要一个新的处理算法。设计/方法:LGS过渡的保健顾问委员会(2017年11月)会见了开发一种新的处理算法。预备调查抗癫痫药物(aed)最常用于LGS治疗成人形成分类aed成1 - 3层的基础。结果:频繁的重新评估与LGS的成人提出处理算法的基石。一级包括fda批准的LGS aed (rufinamide clobazam,拉莫三嗪,托吡酯)和丙戊酸钠。二级包括aed常用治疗LGS (levetiracetam, perampanel zonisamide)和大麻二酚(fda批准;最后的位置将需要额外的临床经验)。第三列包含潜在有价值的aed缺乏系统的试验数据来支持他们的功效(lacosamide、cenobamate brivaracetam)或不利的毒性(felbamate)。aed要避免包括那些不经常使用,这可能加剧某些癫痫类型(卡马西平,eslicarbazepine,加巴喷丁、苯妥英普瑞巴林奥卡西平,氨己烯酸)。 Therapies complementary to AEDs were also assessed and included non-pharmacologic interventions, community services, and psychosocial treatments.Conclusions: Effective and appropriate medications are recommended for treatment of LGS in adults in Tiers 1 and 2 of the treatment algorithm. Tier 3 AEDs lack efficacy data or have unfavorable toxicity. AEDs to be avoided were also identified.Funding: The advisory board was convened and funded by Eisai Inc. All authors were participants of the advisory board and responsible for the decision to develop and submit this abstract. Medical writing support, under the direction of the authors, was funded by Eisai Inc., in accordance with GPP3 guidelines.Disclosure: Dr. Kothare has nothing to disclose. Dr. Aboumatar has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai, Sun Orion. Dr. Burdette has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with UCB, Sun Ovion, Neuropace, Eisai. Dr. Burdette has received research support from Neuropace, Eisai, Eugenix. Dr. Kuzniecky has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai. Dr. Montouris has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai, Lundbeck, SK Life, UCB Pharma, Accorda Therapeutics. Dr. Rosenfeld has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with UCB Pharma, Sunovion Pharmaceuticals, SK Life Science and Eisai. Dr. Rosenfeld has received research support from Greenwich Biosciences, UCB Pharma, SK Life, Neurelis, Takeda Pharmaceutical Company and Ovid Therapeutics, Inc. Dr. Chung has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ucb, Sunovion, Lundbeck, Eisai. Dr. Chung has received research support from Ucb, SK Life Sciences.